Development of a murine model of lymph node metastases suitable for immunotoxicity studies

Journal of Pharmacological and Toxicological Methods

Volumn 63, Issue 3, 2011, Pages 236-249

  Egenolf, Devon D ^a   Rafferty, Patricia ^a   Brosnan, Kerry ^a   Walker, Mindi ^a   Jordan, Jarrat ^a   Makropoulos, Dorie ^a   Kavalkovich, Karl ^a   Watson, Sharon ^a   Johns, Laura ^a   Volk, Amy ^a   Bugelski, Peter J ^a  

^a CENTOCOR INC   (United States)

Author keywords

Immunosuppressive drugs; Immunotoxicity; Lymph node; Metastases; Methods; Microscopy; Natural killer cells; Neoplasia; Quantum dots

Indexed keywords

ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GANGLIOTETRAOSYLCERAMIDE; GANGLIOTETRAOSYLCERAMIDE ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; QUANTUM DOT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CELL LABELING; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; FEMALE; IMMUNOCOMPETENCE; IMMUNOSURVEILLANCE; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MICROFLUOROMETRY; MOLECULAR RECOGNITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TOXICITY TESTING; TUMOR VOLUME; VALIDATION PROCESS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; LYMPHATIC METASTASIS; MICE; MICE, INBRED C3H; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL;

MURINAE; MUS;

EID: 79954619840     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.12.001     Document Type: Article

References (118)

1. Ahmed S., Okamoto M., Oshikawa T., Tano T., Sasai A., Kan S., et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. Journal of Immunotherapy 2004, 27:432-441.
2. Ballou B., Lagerholm B.C., Ernst L.A., Bruchez M.P., Waggoner A.S. Noninvasive imaging of quantum dots in mice. Bioconjugate Chemistry 2004, 15:79-86.
3. Bancroft G., Kelly J. Macrophage activation and innate resistance to infection in SCID mice. Immunobiology 1994, 191:424-431.
4. Barbera-Guillem E., Barcelo J.R., Urcelay B., Alonso-Varona A.I., Vidal-Vanaclocha F. Noncorrelation between implantation and growth of tumor cells for their final metastatic efficiency. Invasion & Metastasis 1988, 8:266-284.
5. Barbera-Guillem E., Canavate M.L., Lopez de Tejada I., Vidal-Vanaclocha F. Influence of host defenses on the hepatic colonization of B16F10 melanoma cells. Clinical & Experimental Metastasis 1988, 6:153-169.
6. Baschong W., Suetterlin R., Laeng R.H. Control of autofluorescence of archival formaldehyde-fixed, paraffin-embedded tissue in confocal laser scanning microscopy (CLSM). The Journal of Histochemistry and Cytochemistry 2001, 49:1565-1572.
7. Bauer S., Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
8. Beck B.N., Gillis S., Henney C.S. Display of the neutral glycolipid ganglio-n-tetraosylceramide (asialo GM1) on cells of the natural killer and T lineages. Transplantation 1982, 33:118-122.
9. Boffa D., Luan F., Thomas D., Yang H., Sharma V., Lagman M., et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clinical Cancer Research 2004, 10:293-300.
10. Borel J. Biological effects of cyclosporin A: A new antilymphocytic agent. Agent and Actions 1976, 6.
11. Bryson J.S., Jennings C.D., Lowery D.M., Carlson S.L., Pflugh D.L., Caywood B.E., et al. Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease. Bone Marrow Transplantation 1999, 23:363-372.
12. Bucy R.P., Xu X.Y., Li J., Huang G. Cyclosporin A-induced autoimmune disease in mice. Journal of Immunology 1993, 151:1039-1050.
13. Calzascia T., Di Berardino-Besson W., Wilmotte R., Masson F., de Tribolet N., Dietrich P.Y., et al. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. Journal of Immunology 2003, 171:2187-2191.
14. Cerwenka A., Bakker A.B., McClanahan T., Wagner J., Wu J., Phillips J.H., et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000, 12:721-727.
15. Cerwenka A., Baron J.L., Lanier L.L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:11521-11526.
16. Cottier H., Turk J., Sobin L. A proposal for a standardized system of reporting human lymph node morphology in relation to immunological function. Journal of Clinical Pathology 1973, 26:317-331.
17. Cox C., Teknos T., Barrios M., Brewer G., Dick R., Merajver S. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. The Laryngoscope 2001, 111:696-701.
18. Dasgupta S., Bhattacharya-Chatterjee M., O'Malley B.J., Chatterjee S. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer. Journal of Immunology 2005, 175:5541-5550.
19. Dass C.R., Choong P.F. GFP expression alters osteosarcoma cell biology. DNA and Cell Biology 2007, 26:599-601.
20. de Ruiter J., Cramer S.J., Smink T., van Putten L.M. The facilitation of tumour growth in the lung by cyclophosphamide in artificial and spontaneous metastases models. European Journal of Cancer (Oxford) 1979, 15:1139-1149.
21. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., Raulet D.H. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nature Immunology 2000, 1:119-126.
22. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413:165-171.
23. Diefenbach A., Tomasello E., Lucas M., Jamieson A.M., Hsia J.K., Vivier E., et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nature Immunology 2002, 3:1142-1149.
24. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994, 1:447-456.
25. Dooley M., Ginzler E. Newer therapeutic approaches for systemic lupus erythematosus: Immunosuppressive agents. Rheumatic Diseases Clinics of North America 2006, 32:91-102.
26. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology 2002, 3:991-998.
27. Eccles S.A., Heckford S.E., Alexander P. Effect of cyclosporin A on the growth and spontaneous metastasis of syngeneic animal tumours. British Journal of Cancer 1980, 42:252-259.
28. Edwards A., Sumner M., Rowland G., Hurd C. Changes in lymphoreticular tissues during growth of a murine adenocarcinoma. I Histology and weight of lymph nodes, spleen and thymus. Journal of the National Cancer Institute 1971, 47:301-311.
29. Fotos J.S., Patel V.P., Karin N.J., Temburni M.K., Koh J.T., Galileo D.S. Automated time-lapse microscopy and high-resolution tracking of cell migration. Cytotechnology 2006, 51:7-19.
30. Gao X., Cui Y., Levenson R.M., Chung L.W.K., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotechnology 2004, 22:969-976.
31. Gilfillan S., Ho E.L., Cella M., Yokoyama W.M., Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nature Immunology 2002, 3:1150-1155.
32. Girardi M. Immunosurveillance and immunoregulation by gammadelta T cells. Journal of Investigative Dermatology 2006, 126:25-31.
33. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001, 294:605-609.
34. Gorelik E., Segal S., Feldman M. Host's immune state and kinetics of local tumor growth control-Progression of postoperative lung metastasis. Recent Results in Cancer Research 1980, 75:20-28.
35. Guerra N., Tan Y.X., Joncker N.T., Choy A., Gallardo F., Xiong N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
36. Haliotis T., Ball J.K., Dexter D., Roder J.C. Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice. International Journal of Cancer 1985, 35:505-513.
37. Halloran P.F., Kung L., Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplantation Proceedings 1998, 30:2167-2170.
38. Hanna N., Burton R.C. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastases in vivo. Journal of Immunology 1981, 127:1754-1758.
39. Hargadon K.M., Brinkman C.C., Sheasley-O'neill S.L., Nichols L.A., Bullock T.N., Engelhard V.H. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. Journal of Immunology 2006, 177:6081-6090.
40. Hewitt H., Blake E. Further studies on the relationship between lymphatic dissemination and lymphnodal metastases in non-immunogenic murine tumors. British Journal of Cancer 1977, 35:415-419.
41. Hoffmann J., Schirner M., Menrad A., Schneider M.R. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Research 1997, 57:3847-3851.
42. Horna P., Sotomayor E.M. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Current Cancer Drug Targets 2007, 7:41-53.
43. Hoshida T., Isaka N., Hagendoorn J., di Tomaso E., Chen Y.-L., Pytowski B., et al. Imaging steps of lymphatic metastases reveal the vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications. Cancer Research 2006, 66:8065-8075.
44. Hume D., Merrill J., Miller B., GW T. Experiences with renal homotransplantations in the human: Report of nine cases. The Journal of Clinical Investigation 1955, 34:327-382.
45. Ishikawa M., Koga Y., Hosokawa M., Kobayashi H. Augmentation of B16 melanoma lung colony formation in C57BL/6 mice having marked granulocytosis. International Journal of Cancer 1986, 37:919-924.
46. Jackson H., Muhammad O., Daneshvar H., Nelms J., Popescu A., Vogelbaum M.A., et al. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery 2007, 60:524-529. discussion 529-530.
47. Jeong H., Lee H., Ko Y., Son Y. Vaccinations with dendritic cells primed with apoptotic tumor cells can elicit preventive antitumor immunity in a poorly immunogenic animal model of squamous cell carcinoma. The Laryngoscope 2007, 117:1588-1593.
48. Kahan B. Sirolimus: A comprehensive review. Expert Opinion on Pharmacotherapy 2001, 2:1903-1917.
49. Kajiwara T., Tomita Y., Okano S., Iwai T., Yasunami Y., Yoshikai Y., et al. Effects of cyclosporin A on the activation of natural killer T cells induced by alpha-galactosylceramide. Transplantation 2007, 83:184-192.
50. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:7556-7561.
51. Khariwala, S. S., Kjaergaard, J., Lorenz, R., Van Lente, F., Shu, S., and Strome, M. (2006). Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII).[Erratum appears in Laryngoscope. 2006 Jul;116(7 Pt 1):1302]. Laryngoscope 116, 814-820.
52. Khurana D., Martin E.A., Kasperbauer J.L., O'Malley B.W., Salomao D.R., Chen L., et al. Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head & Neck 2001, 23:899-906.
53. Kind P.R.N., Gordon M., Laverick M., Nias A.H.W., Slavin B.M. The effect C3H mouse mammary tumour on the levels of serum and urine analytes in vivo. British Journal of Cancer 1985, 52:607-612.
54. Klein G., Imreh S., Zabarovsky E.R. Why do we not all die of cancer at an early age?. Advances in Cancer Research 2007, 98:1-16.
55. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
56. Kotloff D.B., Bosma M.J., Ruetsch N.R. V(D)J recombination in peritoneal B cells of leaky scid mice. Journal of Experimental Medicine 1993, 178:1981-1994.
57. Krosl G., Korbelik M., Dougherty T. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. British Journal of Cancer 1995, 71:549-555.
58. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
59. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359.
60. Kundig T.M., Bachmann M.F., DiPaolo C., Simard J.J., Battegay M., Lother H., et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995, 268:1343-1347.
61. Kurki P. Safety aspects of the long term cyclosporin A therapy. Scandinavian Journal of Rheumatology 1992, 95:35-38.
62. Laatikainen A., Syrjänen K., Mäntyjärvi R., P., T. Immune response against P815X2 mastocytoma growing in syngeneic DBA/2 mice. IV. Lymph node immunoreactivity and cell-mediated cytotoxicity. Neoplasma 1987, 34:431-439.
63. Lim D.-G., Joe I.-Y., Park Y.-H., Chang S.-H., Wee Y.-M., Han D.-J., et al. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transplant Immunology 2007, 18:94-100.
64. Løvik M. The SCID (severe combined immunodeficiency) mouse - its biology and use in immunotoxicological research. Archives of Toxicology Supplement 1995, 17:455-467.
65. Maddox J., Soltani K. Risk of nonmelanoma skin cancer with azathioprine use. Inflammatory Bowel Disease 2008, 14:1425-1431.
66. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
67. Matsuda S., Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000, 47:119-125.
68. Matsui M., Kishida T., Nakano H., Yoshimoto K., Shin-Ya M., Shimada T., et al. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Research 2009, 69:2523-2530.
69. Michalet X., Pinaud F.F., Bentolila L.A., Tsay J.M., Doose S., Li J.J., et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005, 307:538-544.
70. Milas L., Faykus M.J., McBride W., Hunter N., LJ., P. Concomitant development of granulocytosis and enhancement of metastases formation in tumor-bearing mice. Clinical & Experimental Metastasis 1984, 2:181-190.
71. Morgan N.Y., English S., Chen W., Chernomordik V., Russo A., Smith P.D., et al. Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Academic Radiology 2005, 12:313-323.
72. Morgan D.J., Kreuwel H.T., Fleck S., Levitsky H.I., Pardoll D.M., Sherman L.A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. Journal of Immunology 1998, 160:643-651.
73. Motoyoshi Y., Kaminoda K., Saitoh O., Hamasaki K., Nakao K., Ishii N., et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncology Reports 2006, 16:141-146.
74. Murphy K., Wardak A., Beckett M., Lopez C., Mehta N., Kimchi E., et al. Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Cancer Chemotherapy and Pharmacology 2005, 56:317-321.
75. Myers J., Mank-Seymour A., Zitvogel L., Storkus W., Clarke M., Johnson C., et al. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. The Laryngoscope 1998, 108:261-268.
76. Noga S.J., Horwitz L., Kim H., Laulis M.K., Hess A.D. Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity. Journal of Hematotherapy 1992, 1:75-84.
77. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001, 411:1058-1064.
78. O'Malley B.J., Cope K., Johnson C., MR., S. A new immunocompetent murine model for oral cancer. Archives of Otolaryngology - Head & Neck Surgery 1997, 123:20-24.
79. Pelley J.L., Daar A.S., Saner M.A. State of academic knowledge on toxicity and biological fate of quantum dots. Toxicological Sciences 2009, 112:276-296.
80. Prestwich R., Errington F., Hatfield P., Merrick A., Ilett E., Selby P., et al. The immune system - Is it relevant to cancer development, progression and treatment?. Clinical Oncology 2008, 20:101-112.
81. Preynat-Seauve O., Contassot E., Schuler P., Piguet V., French L.E., Huard B. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Research 2007, 67:5009-5016.
82. Prud'homme G.J., Parfrey N.A., Vanier L.E. Cyclosporine-induced autoimmunity and immune hyperreactivity. Autoimmunity 1991, 9:345-356.
83. Qin H., Valentino J., Manna S., Tripathi P., Bhattacharya-Chatterjee M., Foon K., et al. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Molecular Therapy: the Journal of the American Society of Gene Therapy 2001, 4:551-558.
84. Ramsay J., Suit H.D., Sedlacek R. Experimental studies on the incidence of metastases after failure of radiation treatment and the effect of salvage surgery. International Journal of Radiation Oncology, Biology, Physics 1988, 14:1165-1168.
85. Re F., Srinivasan R., Igarashi T., Marincola F., Childs R. Green fluorescent protein expression in dendritic cells enhances their immunogenicity and elicits specific cytotoxic T-cell responses in humans. Experimental Hematology 2004, 32:210-217.
86. Redente E.F., Orlicky D.J., Bouchard R.J., Malkinson A.M. Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. The American Journal of Pathology 2007, 170:693-708.
87. Roh J., Sung M., Park S., Heo D., Lee D., Kim K. Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Research 2004, 64:3230-3235.
88. Rushfeldt C., Sveinbjornsson B., Seljelid R., Smedsrod B. Early events of hepatic metastasis formation in mice: Role of Kupffer and NK-cells in natural and interferon-gamma-stimulated defense. The Journal of Surgical Research 1999, 82:209-215.
89. Ryffel B., Mihatsch M., Fisher G. Immunosuppression and cancer: The ciclosporin case. Drug and Chemical Toxicology 1992, 15:95-115.
90. Saijo N., Ozaki A., Beppu Y., Takahashi K., Fujita J., Sasaki Y., et al. Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GM1 antibody or anticancer agents. Journal of Cancer Research and Clinical Oncology 1984, 107:157-163.
91. Salup R.R., Herberman R.B., Wiltrout R.H. Role of natural killer activity in development of spontaneous metastases in murine renal cancer. The Journal of Urology 1985, 134:1236-1241.
92. Scioscia K., Snyderman C., Rueger R., Reddy J., D'Amico F., Comsa S., et al. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs. American Journal of Otolaryngology 1997, 18:1-8.
93. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
94. Shiflett S., Kaplan J., Ward D. Chediak-Higashi Syndrome: A rare disorder of lysosomes and lysosome related organelles. Pigment Cell Research 2002, 15.
95. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. The Journal of Experimental Medicine 2000, 191:661-668.
96. Smyth M.J., Thia K.Y., Street S.E., MacGregor D., Godfrey D.I., Trapani J.A. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. The Journal of Experimental Medicine 2000, 192:755-760.
97. Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97:192-197.
98. Stroh M., Zimmer J.P., Duda D.G., Levchenko T.S., Cohen K.S., Brown E.B., et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nature Medicine 2005, 11:678-682.
99. Strome S., Dong H., Tamura H., Voss S., Flies D., Tamada K., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Research 2003, 63:6501-6505.
100. Suit H., Sedlacek R., Zietman A. Quantitative transplantation assays of spontaneous tumors of the C3H mouse as allografts in athymic NCr/Sed-nu/nu nude mice and isografts in C3Hf/Sed mice. Cancer Research 1988, 48:4525-4528.
101. Thomson A.W. The effects of cyclosporin A on non-T cell components of the immune system. Journal of Autoimmunity 1992, 5(Suppl A):167-176.
102. Tracey D., Klareskog L., Sasso E., Salfeld J., Tak P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacology & Therapeutics 2008, 117:244-279.
103. Ulrich C., Kanitakis J., Stockfleth E., Euvrard S. Skin cancer in organ transplant recipients - Where do we stand today?. American Journal of Transplantation 2008, 8:2192-2198.
104. Volpe J.P., Hunter N., Basic I., Milas L. Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clinical & Experimental Metastasis 1985, 3:281-294.
105. Volpe C.M., Mehta N., Kim U., Hordines J., Doerr R.J., Cohen S.A. AsGM1+ NK cells prevent metastasis of invading LD-MCA-38 tumor cells in the nude mouse. The Journal of Surgical Research 1999, 84:157-161.
106. Voura E.B., Jaiswal J.K., Mattoussi H., Simon S.M. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nature Medicine 2004, 10:993-998.
107. Wang H., Grzywacz B., Sukovich D., McCullar V., Cao Q., Lee A.B., et al. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood 2007, 110:1530-1539.
108. Watson A., Wu X., Bruchez M. Lighting up cells with quantum dots. Biotechniques 2003, 34:296-300.
109. Weischer M., Rocken M., Berneburg M. Calcineurin inhibitors and rapamycin: Cancer protection or promotion?. Experimental Dermatology 2007, 16:385-393.
110. Williams Y., Byrne S., Bashir A., Davies A., Gun'Ko Y., Kelleher D., Volkov Y. Comparison of three cell fixation methods for high content analysis assays utilizing quantum dots. Journal of Microscopy 2008, 232:91-98.
111. Willimsky G., Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
112. Wolkers M.C., Stoetter G., Vyth-Dreese F.A., Schumacher T.N. Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses. Journal of Immunology 2001, 167:3577-3584.
113. Wong R., Chan M., Yu Z., Ghossein R., Ngai I., Adusumilli P., et al. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clinical Cancer Research 2004, 10:4509-4516.
114. Wong R., Patel S., Kim S., DeMatteo R., Malhotra S., Bennett J., et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Human Gene Therapy 2001, 12:235-265.
115. Wu J., Song Y., Bakker A.B., Bauer S., Spies T., Lanier L.L., et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999, 285:730-732.
116. Xing Z., Zganiacz A., Wang J., Sharma S.K. Enhanced protection against fatal mycobacterial infection in SCID beige mice by reshaping innate immunity with IFN-gamma transgene. Journal of Immunology 2001, 167:375-383.
117. Yu P., Spiotto M.T., Lee Y., Schreiber H., Fu Y.X. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. The Journal of Experimental Medicine 2003, 197:985-995.
118. Zafar S., Howell D., Gockerman J. Malignancy after solid organ transplantation: an overview. The Oncologist 2008, 13:769-778.